glp-1 pancreatitis class action in michigan Risk of pancreatic cancer associated with receptor agonist therapy Glucagon-like Peptide-1 Receptor Agonist Use

These effects result in very significant weight loss (15-20% of initial body weight), i.e., of the same order of magnitude as that obtained by bariatric surgery

Now that supply has caught up with demand, you can be certain that Novo Nordisk and Eli Lilly will be increasing their marketing efforts of GLP-1 availability through a variety of approaches, including direct to consumer advertising

It is important to recognize that the cardiovascular and renal benefits of GLP-1 medications typically outweigh the potential for retinopathy progression in appropriately selected patients, and discontinuing these medications due to unfounded concerns about vision may result in worse overall health outcomes

New England Journal of Medicine, 384 (11), 9891002

This could suggest consideration of a potential benefit of L-T4 administration in treating even mild TH deficiency to improve the insulin resistance and dyslipidemia that is associated with SHypo (179)